{"id":20973,"date":"2023-11-02T10:06:36","date_gmt":"2023-11-02T09:06:36","guid":{"rendered":"https:\/\/ggba.swiss\/?p=20973"},"modified":"2023-11-02T10:11:01","modified_gmt":"2023-11-02T09:11:01","slug":"epfl-and-novochizol-to-collaborate-on-designing-more-efficient-immunotherapies","status":"publish","type":"post","link":"https:\/\/ggba.swiss\/en\/epfl-and-novochizol-to-collaborate-on-designing-more-efficient-immunotherapies\/","title":{"rendered":"EPFL and Novochizol to collaborate on designing more efficient immunotherapies"},"content":{"rendered":"\n

Novochizol<\/a> is a trailblazing start-up located at the BioArk<\/a> life sciences campus in Monthey (canton of Valais), and specializes in the revolutionary transformation of chitosan\u2014a naturally occurring biopolymer\u2014into Novochizol, a technology that notably enhances the properties of standard chitosans. This innovation positions Novochizol as a versatile platform across diverse sectors including pharma, biotech, and agriculture, for its ability to improve drug delivery systems, particularly by facilitating local administration of treatments directly to disease sites with minimal systemic exposure.<\/p>\n\n\n\n

Working in concert with Novochizol is the Laboratory of Biomaterials for Immunoengineering<\/a> at EPFL, led by Prof. Li Tang. The lab is at the forefront of immunoengineering, an interdisciplinary field that marries the intricacies of immune responses with cutting-edge bioengineering techniques. Their mission is to develop novel, efficacious therapies against cancer and other diseases by intricately manipulating metabolic, cellular, and mechanical elements to modulate immunity with precision.<\/p>\n\n\n\n

In the pursuit of cancer cures, the EPFL and Novochizol are embarking on a promising joint-venture to design immunotherapies with superior safety and efficacy. Backed by Innosuisse, the project has secured a budget of CHF 1.1 million, of which CHF 498,000 comes from an Innosuisse Grant, underscoring the confidence in this endeavor\u2019s potential to make significant inroads against solid cancers.<\/p>\n\n\n\n

The three-year research initiative will delve into the capabilities of Novochizol nanoparticles. These are designed to safely ferry potent doses of cancer-fighting agents like cytokines and immune checkpoint inhibitors directly into tumors. The innovative use of Novochizol seeks to overcome the current limitations of immunotherapies\u2014ensuring the active agents remain protected and localized, thereby reducing the risk of systemic toxicities.<\/p>\n\n\n\n

Redefining treatment paradigms in oncology<\/h4>\n\n\n\n

“Delivering cytokines and immune checkpoint inhibitors into tumors with Novochizol nanoparticles may redefine treatment paradigms in oncology,” said Prof. Li Tang. The collaboration with Novochizol could transform not only cancer treatments but also extend to various medical conditions that benefit from localized drug delivery.<\/p>\n\n\n\n

Through this partnership, Novochizol\u2019s adoption could accelerate numerous third-party drug development projects, potentially aiding millions of patients worldwide.<\/p>\n\n\n\n

The synergy between the EPFL\u2019s immunoengineering expertise and Novochizol’s novel nanoparticle delivery system embodies the pioneering spirit at the heart of modern medical research. With the financial impetus from Innosuisse, this collaboration may pave the way towards more effective and patient-friendly cancer treatments.<\/p>\n","protected":false},"excerpt":{"rendered":"

A groundbreaking collaboration between EPFL’s Laboratory of Biomaterials for Immunoengineering and Novochizol aims to revolutionize cancer treatment.<\/p>\n","protected":false},"author":6,"featured_media":20974,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"mc4wp_mailchimp_campaign":[],"footnotes":""},"categories":[833],"tags":[912,949,894,883,902,886,901],"class_list":["post-20973","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-life-science","tag-biotech","tag-education-en","tag-financing","tag-oncology","tag-personalized-medicine","tag-rd","tag-technology-park"],"acf":[],"yoast_head":"\nEPFL and Novochizol to collaborate on efficient immunotherapies<\/title>\n<meta name=\"description\" content=\"A collaboration between EPFL's Laboratory of Biomaterials for Immunoengineering and Novochizol aims to revolutionize cancer treatment.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ggba.swiss\/en\/epfl-and-novochizol-to-collaborate-on-designing-more-efficient-immunotherapies\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"EPFL and Novochizol to collaborate on efficient immunotherapies\" \/>\n<meta property=\"og:description\" content=\"A collaboration between EPFL's Laboratory of Biomaterials for Immunoengineering and Novochizol aims to revolutionize cancer treatment.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ggba.swiss\/en\/epfl-and-novochizol-to-collaborate-on-designing-more-efficient-immunotherapies\/\" \/>\n<meta property=\"og:site_name\" content=\"Greater Geneva Bern area\" \/>\n<meta property=\"article:published_time\" content=\"2023-11-02T09:06:36+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-11-02T09:11:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ggba.swiss\/app\/uploads\/2023\/11\/Novochizol-1180x811-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1180\" \/>\n\t<meta property=\"og:image:height\" content=\"811\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Pierre-Yves Oehrli\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Pierre-Yves Oehrli\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/ggba.swiss\/en\/epfl-and-novochizol-to-collaborate-on-designing-more-efficient-immunotherapies\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/ggba.swiss\/en\/epfl-and-novochizol-to-collaborate-on-designing-more-efficient-immunotherapies\/\"},\"author\":{\"name\":\"Pierre-Yves Oehrli\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"headline\":\"EPFL and Novochizol to collaborate on designing more efficient immunotherapies\",\"datePublished\":\"2023-11-02T09:06:36+00:00\",\"dateModified\":\"2023-11-02T09:11:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/en\/epfl-and-novochizol-to-collaborate-on-designing-more-efficient-immunotherapies\/\"},\"wordCount\":389,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/ggba.swiss\/en\/epfl-and-novochizol-to-collaborate-on-designing-more-efficient-immunotherapies\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2023\/11\/Novochizol-1180x811-1.jpg\",\"keywords\":[\"Biotech\",\"Education\",\"Financing\",\"Oncology\",\"Personalized Medicine\",\"R&D\",\"Technology Park\"],\"articleSection\":[\"Life sciences\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/ggba.swiss\/en\/epfl-and-novochizol-to-collaborate-on-designing-more-efficient-immunotherapies\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ggba.swiss\/en\/epfl-and-novochizol-to-collaborate-on-designing-more-efficient-immunotherapies\/\",\"url\":\"https:\/\/ggba.swiss\/en\/epfl-and-novochizol-to-collaborate-on-designing-more-efficient-immunotherapies\/\",\"name\":\"EPFL and Novochizol to collaborate on efficient immunotherapies\",\"isPartOf\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/en\/epfl-and-novochizol-to-collaborate-on-designing-more-efficient-immunotherapies\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/ggba.swiss\/en\/epfl-and-novochizol-to-collaborate-on-designing-more-efficient-immunotherapies\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2023\/11\/Novochizol-1180x811-1.jpg\",\"datePublished\":\"2023-11-02T09:06:36+00:00\",\"dateModified\":\"2023-11-02T09:11:01+00:00\",\"author\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"description\":\"A collaboration between EPFL's Laboratory of Biomaterials for Immunoengineering and Novochizol aims to revolutionize cancer treatment.\",\"breadcrumb\":{\"@id\":\"https:\/\/ggba.swiss\/en\/epfl-and-novochizol-to-collaborate-on-designing-more-efficient-immunotherapies\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ggba.swiss\/en\/epfl-and-novochizol-to-collaborate-on-designing-more-efficient-immunotherapies\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/ggba.swiss\/en\/epfl-and-novochizol-to-collaborate-on-designing-more-efficient-immunotherapies\/#primaryimage\",\"url\":\"https:\/\/ggba.swiss\/app\/uploads\/2023\/11\/Novochizol-1180x811-1.jpg\",\"contentUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2023\/11\/Novochizol-1180x811-1.jpg\",\"width\":1180,\"height\":811,\"caption\":\"Novochizol technology quantitatively transforms single linear chitosan molecules into cross-linked, uniformly sized nanospheres. | \u00a9 Novochizol\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ggba.swiss\/en\/epfl-and-novochizol-to-collaborate-on-designing-more-efficient-immunotherapies\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ggba.swiss\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"EPFL and Novochizol to collaborate on designing more efficient immunotherapies\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\",\"url\":\"https:\/\/staging.ggba.swiss\/en\/\",\"name\":\"Greater Geneva Bern area\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\",\"name\":\"Pierre-Yves Oehrli\",\"url\":\"https:\/\/ggba.swiss\/en\/author\/pierre-yves-oehrli\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"EPFL and Novochizol to collaborate on efficient immunotherapies","description":"A collaboration between EPFL's Laboratory of Biomaterials for Immunoengineering and Novochizol aims to revolutionize cancer treatment.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ggba.swiss\/en\/epfl-and-novochizol-to-collaborate-on-designing-more-efficient-immunotherapies\/","og_locale":"en_US","og_type":"article","og_title":"EPFL and Novochizol to collaborate on efficient immunotherapies","og_description":"A collaboration between EPFL's Laboratory of Biomaterials for Immunoengineering and Novochizol aims to revolutionize cancer treatment.","og_url":"https:\/\/ggba.swiss\/en\/epfl-and-novochizol-to-collaborate-on-designing-more-efficient-immunotherapies\/","og_site_name":"Greater Geneva Bern area","article_published_time":"2023-11-02T09:06:36+00:00","article_modified_time":"2023-11-02T09:11:01+00:00","og_image":[{"width":1180,"height":811,"url":"https:\/\/ggba.swiss\/app\/uploads\/2023\/11\/Novochizol-1180x811-1.jpg","type":"image\/jpeg"}],"author":"Pierre-Yves Oehrli","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Pierre-Yves Oehrli","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ggba.swiss\/en\/epfl-and-novochizol-to-collaborate-on-designing-more-efficient-immunotherapies\/#article","isPartOf":{"@id":"https:\/\/ggba.swiss\/en\/epfl-and-novochizol-to-collaborate-on-designing-more-efficient-immunotherapies\/"},"author":{"name":"Pierre-Yves Oehrli","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"headline":"EPFL and Novochizol to collaborate on designing more efficient immunotherapies","datePublished":"2023-11-02T09:06:36+00:00","dateModified":"2023-11-02T09:11:01+00:00","mainEntityOfPage":{"@id":"https:\/\/ggba.swiss\/en\/epfl-and-novochizol-to-collaborate-on-designing-more-efficient-immunotherapies\/"},"wordCount":389,"commentCount":0,"image":{"@id":"https:\/\/ggba.swiss\/en\/epfl-and-novochizol-to-collaborate-on-designing-more-efficient-immunotherapies\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2023\/11\/Novochizol-1180x811-1.jpg","keywords":["Biotech","Education","Financing","Oncology","Personalized Medicine","R&D","Technology Park"],"articleSection":["Life sciences"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/ggba.swiss\/en\/epfl-and-novochizol-to-collaborate-on-designing-more-efficient-immunotherapies\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/ggba.swiss\/en\/epfl-and-novochizol-to-collaborate-on-designing-more-efficient-immunotherapies\/","url":"https:\/\/ggba.swiss\/en\/epfl-and-novochizol-to-collaborate-on-designing-more-efficient-immunotherapies\/","name":"EPFL and Novochizol to collaborate on efficient immunotherapies","isPartOf":{"@id":"https:\/\/staging.ggba.swiss\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ggba.swiss\/en\/epfl-and-novochizol-to-collaborate-on-designing-more-efficient-immunotherapies\/#primaryimage"},"image":{"@id":"https:\/\/ggba.swiss\/en\/epfl-and-novochizol-to-collaborate-on-designing-more-efficient-immunotherapies\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2023\/11\/Novochizol-1180x811-1.jpg","datePublished":"2023-11-02T09:06:36+00:00","dateModified":"2023-11-02T09:11:01+00:00","author":{"@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"description":"A collaboration between EPFL's Laboratory of Biomaterials for Immunoengineering and Novochizol aims to revolutionize cancer treatment.","breadcrumb":{"@id":"https:\/\/ggba.swiss\/en\/epfl-and-novochizol-to-collaborate-on-designing-more-efficient-immunotherapies\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ggba.swiss\/en\/epfl-and-novochizol-to-collaborate-on-designing-more-efficient-immunotherapies\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ggba.swiss\/en\/epfl-and-novochizol-to-collaborate-on-designing-more-efficient-immunotherapies\/#primaryimage","url":"https:\/\/ggba.swiss\/app\/uploads\/2023\/11\/Novochizol-1180x811-1.jpg","contentUrl":"https:\/\/ggba.swiss\/app\/uploads\/2023\/11\/Novochizol-1180x811-1.jpg","width":1180,"height":811,"caption":"Novochizol technology quantitatively transforms single linear chitosan molecules into cross-linked, uniformly sized nanospheres. | \u00a9 Novochizol"},{"@type":"BreadcrumbList","@id":"https:\/\/ggba.swiss\/en\/epfl-and-novochizol-to-collaborate-on-designing-more-efficient-immunotherapies\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ggba.swiss\/en\/"},{"@type":"ListItem","position":2,"name":"EPFL and Novochizol to collaborate on designing more efficient immunotherapies"}]},{"@type":"WebSite","@id":"https:\/\/staging.ggba.swiss\/en\/#website","url":"https:\/\/staging.ggba.swiss\/en\/","name":"Greater Geneva Bern area","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41","name":"Pierre-Yves Oehrli","url":"https:\/\/ggba.swiss\/en\/author\/pierre-yves-oehrli\/"}]}},"_links":{"self":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts\/20973","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/comments?post=20973"}],"version-history":[{"count":2,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts\/20973\/revisions"}],"predecessor-version":[{"id":20978,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts\/20973\/revisions\/20978"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/media\/20974"}],"wp:attachment":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/media?parent=20973"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/categories?post=20973"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/tags?post=20973"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}